This page lists the medical oncology hospitals in our directory offering Salivary Gland Cancer Treatment in Mumbai, India, including Nanavati Super Specialty Hospital, Kokilaben Dhirubhai Ambani Hospital, Tata Memorial Hospital, Apollo Hospitals, Navi Mumbai and others. Each listing links through to the hospital's full profile page.
Ask us about salivary gland cancer treatment in Mumbai, India
Share a few details and our care coordination team will get back to you with next steps.
Compare 17 accredited hospitals for Medical Oncology in Mumbai, India
Featured🇮🇳 Nanavati Super Specialty Hospital
Ranks #1 in this list by listed rating (5/5 from 12 reviews).
🇮🇳 Kokilaben Dhirubhai Ambani Hospital
Ranks #2 in this list by listed rating (4.8/5 from 1800 reviews).
🇮🇳 Tata Memorial Hospital
Ranks #3 in this list by listed rating (4.8/5 from 2500 reviews).
🇮🇳 Apollo Hospitals, Navi Mumbai
Ranks #4 in this list by listed rating (4.8/5 from 512 reviews).
🇮🇳 Gleneagles Hospital, Mumbai
Ranks #5 in this list by listed rating (4.8/5 from 615 reviews).
🇮🇳 Lilavati Hospital And Research Centre
Ranks #6 in this list by listed rating (4.8/5 from 724 reviews).
🇮🇳 Jaslok Hospital
Ranks #7 in this list by listed rating (4.6/5 from 129 reviews).
🇮🇳 Gleneagles Global Hospitals (Global Hospitals)
Ranks #8 in this list by listed rating (4.6/5 from 183 reviews).
🇮🇳 Medicover Hospital, Navi Mumbai
Ranks #9 in this list by listed rating (4.6/5 from 143 reviews).
🇮🇳 KIMS Hospitals, Thane
Ranks #10 in this list by listed rating (4.6/5 from 58 reviews).
🇮🇳 Fortis Hospital, Mulund
Ranks #11 in this list by listed rating (4.5/5 from 79 reviews).
🇮🇳 Fortis Hiranandani Hospital, Vashi
Ranks #12 in this list by listed rating (4.5/5 from 83 reviews).
🇮🇳 Wockhardt Hospital
Ranks #13 in this list by listed rating (4.4/5 from 30 reviews).
🇮🇳 Wockhardt Super Speciality Hospital
Ranks #14 in this list by listed rating (4.4/5 from 48 reviews).
🇮🇳 S. L. Raheja Hospital
Ranks #15 in this list by listed rating (4.4/5 from 121 reviews).
🇮🇳 Saifee Hospital
Ranks #16 in this list by listed rating (4.3/5 from 97 reviews).
🇮🇳 Dr. L H Hiranandani Hospital
Ranks #17 in this list by listed rating (4.3/5 from 141 reviews).
How we selected these hospitals
A hospital appears on this page when Medical Oncology is among its listed specialties and it is located in Mumbai, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How to Select the Best Hospital for Salivary Gland Cancer Treatment in Mumbai, India?
Choosing the right hospital for salivary gland cancer treatment is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:
International Accreditation
Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.
Specialization
Check that the hospital's listed specialties actually include medical oncology rather than only general care.
Capacity and Track Record
Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.
Transparent Costs
Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.
Understanding Salivary Gland Cancer Treatment
Salivary gland cancer is a rare but complex malignancy requiring subspecialty surgical oncology, advanced radiation techniques, and increasingly, molecularly targeted systemic therapy. With multidisciplinary treatment, five-year survival rates range from 50–95% depending on histological subtype and stage, making early expert intervention critical. GAF Healthcare connects international patients with JCI- and NABH-accredited oncology centres in India and JCI- and DHA-accredited facilities in Dubai and Abu Dhabi, where world-class head-and-neck surgical teams deliver outcomes comparable to leading Western cancer institutes at a fraction of the cost. Hospital Stay: 5–10 days (varies by extent of resection and neck dissection requirement) • Total Stay in Country (Fit-to-Fly): 4–8 weeks (wound healing, post-operative radiotherapy planning, and swallowing rehabilitation must be stable before long-haul flight) • Success Rate: 78–92% (stage-dependent five-year overall survival; highest for low-grade, organ-confined disease)
Clinical Overview
Salivary gland cancers are a heterogeneous group of epithelial malignancies arising in the parotid (70–80% of cases), submandibular, sublingual, or minor salivary glands distributed throughout the oral cavity, oropharynx, and sinonasal tract. The WHO Classification of Head and Neck Tumours (2022) recognises more than 20 distinct histological subtypes — including mucoepidermoid carcinoma (the most common), adenoid cystic carcinoma (notable for perineural invasion and late distant metastasis), acinic cell carcinoma, secretory carcinoma (characterised by ETV6-NTRK3 fusion), salivary duct carcinoma, and carcinoma ex pleomorphic adenoma. Tumour grade (low, intermediate, high) is the single strongest predictor of behaviour: low-grade lesions are frequently cured with surgery alone, whereas high-grade tumours carry a significant risk of regional nodal spread, distant metastasis to lung, bone, or liver, and require multimodal therapy. Physiologically, salivary gland tumours create compressive and invasive effects that extend well beyond glandular function. Parotid malignancies threaten the facial nerve (CN VII), and perineural spread along cranial nerves can extend intracranially, producing facial palsy, pain, or numbness. Submandibular and sublingual tumours may compromise hypoglossal or lingual nerve function, affecting speech articulation and swallowing. Adenoid cystic carcinoma in particular follows nerve sheaths over decades, making margin-negative resection technically demanding and necessitating long-term radiological surveillance. The disruption of salivary output — whether from the tumour itself or from treatment-related gland loss — profoundly affects dental health, nutritional status, and quality of life. The current standard of care is surgery-first for resectable disease, performed by fellowship-trained head-and-neck surgical oncologists using frozen-section margin analysis. Selective or modified radical neck dissection is performed when regional nodal involvement is confirmed or clinically suspected (T3/T4, high-grade histology, or perineural invasion). Adjuvant intensity-modulated radiation therapy (IMRT) with or without concurrent cisplatin-based chemotherapy is recommended for positive or close surgical margins, high-grade histology, perineural spread, lymphovascular invasion, or extra-nodal extension. For recurrent, metastatic, or unresectable disease, systemic options now include HER2-directed therapy (trastuzumab, ado-trastuzumab emtansine) for HER2-amplified salivary duct carcinoma, androgen deprivation therapy for androgen receptor-positive disease, NTRK inhibitors (larotrectinib, entrectinib) for ETV6-NTRK3-positive secretory carcinomas, and RET inhibitors where applicable — reflecting a rapid evolution toward biomarker-driven precision oncology.
Who is a Candidate?
• Newly diagnosed or recurrent primary salivary gland malignancy confirmed by core-needle or incisional biopsy with histopathological review • Resectable disease (T1–T4a) in the parotid, submandibular, sublingual, or minor salivary glands where curative intent surgery is feasible • Patients with high-grade histology (salivary duct carcinoma, carcinoma ex pleomorphic adenoma, high-grade mucoepidermoid) who require adjuvant IMRT ± systemic therapy • Patients with locally advanced or recurrent disease being evaluated for re-irradiation, palliative surgery, or systemic therapy • Individuals with molecularly characterised metastatic disease (HER2+, NTRK fusion, AR+, RET alteration) seeking targeted therapy protocols • Patients who have received prior treatment abroad and require second-opinion multidisciplinary tumour board review Required Diagnostic Workup Before Travel: • Contrast-enhanced MRI of the primary site (preferred over CT for soft-tissue and perineural invasion detail) • CT chest, abdomen, and pelvis with contrast (staging, distant metastasis) • FDG-PET/CT (recommended for high-grade histology, stage III–IV, or suspected recurrence) • Core-needle biopsy pathology report with WHO histological subtype and grade; immunohistochemistry for S100, p63, SOX10, mammaglobin, GCDFP-15 • Molecular/genomic profiling panel (HER2 FISH/IHC, NTRK fusion testing by NGS or IHC, androgen receptor IHC, Ki-67 proliferation index) • Panoramic dental X-ray and dental oncology clearance prior to radiation planning • Audiogram and renal function panel (if platinum-based chemotherapy is anticipated) • Full blood count, LFTs, thyroid function (baseline for systemic therapy) • ECHO or MUGA scan if HER2-directed therapy or anthracycline-containing regimen is planned • Speech-language pathology and dietetic assessment for swallowing baseline Contraindications and Cautions: • Medically inoperable patients (ASA Class IV or above) may be directed toward definitive radiation or systemic therapy rather than surgery • Distant metastatic disease with high burden may shift intent from curative to palliative — goals of care must be explicitly discussed • Prior high-dose radiation to the head and neck region (cumulative dose constraints must be reviewed before re-irradiation) • Severe coagulopathy, active anticoagulation, or thrombocytopenia requiring correction before surgery • Active systemic infection or uncontrolled comorbidity (uncontrolled diabetes, severe hypertension) must be optimised pre-operatively • Pregnancy: radiation and most systemic agents are contraindicated; surgical management requires multidisciplinary maternal-fetal input
Treatment Options & Approaches
SURGICAL APPROACHES Parotidectomy (Superficial, Total, or Radical): The cornerstone of parotid salivary gland cancer management. Superficial parotidectomy (removal of the lobe lateral to the facial nerve) is performed for low-grade, laterally confined tumours with careful intraoperative facial nerve monitoring using continuous electromyographic (EMG) nerve monitoring systems. Total parotidectomy with facial nerve preservation is performed for deeper lobe involvement. Radical parotidectomy — sacrificing the facial nerve — is reserved for direct tumour invasion of the nerve, with immediate facial nerve reconstruction using the greater auricular nerve, sural nerve graft, or hypoglossal-to-facial anastomosis where feasible. Frozen-section margin analysis at the time of surgery is standard practice to achieve R0 (microscopically clear) resection. Submandibular Gland Excision and Floor-of-Mouth Resection: For submandibular and sublingual primaries, en-bloc resection including the gland, capsule, and adjacent soft tissue is performed. Involvement of the mandible requires marginal or segmental mandibulectomy with microvascular free-flap reconstruction (fibula free flap, radial forearm free flap, anterolateral thigh flap) to restore form and function. Neck Dissection: Selective neck dissection (levels I–III or I–IV) is standard for clinically or radiologically node-positive necks (cN+). Elective neck dissection is recommended for high-grade histology, T3/T4 tumours, or perineural/lymphovascular invasion even when the neck is clinically N0, given occult nodal metastasis rates of 20–49% in these scenarios. Modified radical neck dissection preserving the sternocleidomastoid, internal jugular vein, and accessory nerve is preferred over radical dissection. Robotic-Assisted Surgery (TORS — Transoral Robotic Surgery): For minor salivary gland tumours of the oropharynx, soft palate, or base of tongue, TORS using the da Vinci Surgical System provides magnified, tremor-free, wristed instrumentation in the confined oral cavity. TORS achieves comparable oncological margins with significantly reduced morbidity — no mandibulotomy, shorter hospital stay, faster swallowing recovery — compared to open transcervical or transmandibular approaches. Leading cancer centres in India (Mumbai, Chennai, Delhi) and the UAE (Dubai) have fully operational TORS programmes. SKULL BASE SURGERY: Adenoid cystic carcinoma with perineural spread to the skull base requires endoscopic endonasal skull base surgery or open cranio-facial resection performed by a joint neurosurgery and head-and-neck oncology team. Intraoperative navigation systems (Brainlab, Stryker) are used for precision. RADIATION THERAPY Intensity-Modulated Radiation Therapy (IMRT): The standard adjuvant and definitive radiation modality. IMRT uses computer-optimised beam arrangements to deliver 60–66 Gy to the tumour bed/gross disease while sparing the spinal cord, brainstem, contralateral parotid, mandible, and cochlea — substantially reducing xerostomia, osteoradionecrosis risk, and sensorineural hearing loss compared to older 3D conformal techniques. Volumetric Modulated Arc Therapy (VMAT): An evolution of IMRT using continuous gantry rotation for faster treatment delivery and improved dose conformality. Available at leading centres in both India and the UAE. Proton Beam Therapy: Offered at select Indian centres and internationally, proton therapy is particularly valuable for adenoid cystic carcinoma with skull base involvement, paediatric salivary gland tumours, and re-irradiation scenarios, as the Bragg peak allows maximal dose deposition at target depth with near-zero exit dose. Stereotactic Radiosurgery (SRS/SBRT): For isolated oligometastatic lesions (lung, bone, liver) or localised recurrences not amenable to surgical salvage, SBRT delivers ablative doses in 3–5 fractions with sub-millimetre precision using Varian TrueBeam STx, Elekta Versa HD, or CyberKnife platforms available in both countries. Neutron Capture Therapy / Fast Neutron Radiotherapy: Fast neutron radiotherapy has demonstrated superior local control rates for inoperable or recurrent adenoid cystic carcinoma; availability is limited to specialised international centres, but patients may be counselled regarding referral. SYSTEMIC THERAPY (MEDICAL ONCOLOGY) Cisplatin/Carboplatin + 5-FU or Docetaxel: First-line palliative chemotherapy for platinum-eligible patients with unresectable or metastatic salivary gland cancer. HER2-Directed Therapy: Approximately 20–30% of salivary duct carcinomas overexpress HER2 (IHC 3+ or FISH-amplified). Trastuzumab (Herceptin) monotherapy or in combination with pertuzumab or paclitaxel yields objective response rates of 50–70% in this subgroup. Ado-trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) are emerging options with impressive activity. Androgen Deprivation Therapy (ADT): Salivary duct carcinoma is AR-positive in 70–95% of cases. Androgen deprivation (LHRH agonists + bicalutamide) or enzalutamide produces durable disease control analogous to its role in prostate cancer. NTRK Inhibitors: Larotrectinib (Vitrakvi) and entrectinib (Rozlytrek) produce response rates exceeding 75% in ETV6-NTRK3 fusion-positive secretory carcinomas — an essentially tumour-agnostic, biomarker-selected treatment. Both agents are available in India and the UAE through approved channels. Immune Checkpoint Inhibitors: PD-L1 expression is variable across histological subtypes. Pembrolizumab and nivolumab have modest single-agent activity (ORR ~15%) but may be used in later lines or in high TMB tumours. Clinical trial enrolment is encouraged. RET Inhibitors: Selpercatinib or pralsetinib for RET fusion-positive cases (rare, identified on comprehensive NGS panels).
Recovery
PHASE 1 — REMOTE CONSULTATION AND PRE-TRAVEL PREPARATION (Weeks 1–2) GAF Healthcare's oncology case managers receive your medical records digitally (MRI, PET-CT, biopsy reports, molecular panel). These are reviewed by the assigned head-and-neck surgical oncologist and submitted to the multidisciplinary tumour board (MDT) — comprising head-and-neck surgery, medical oncology, radiation oncology, pathology, radiology, speech therapy, and dentistry — for a virtual pre-consultation opinion. A detailed treatment plan and personalised cost estimate are issued within 48–72 hours. Medical visa application (India) or entry visa/visa-on-arrival process (UAE) is initiated simultaneously. PHASE 2 — ARRIVAL AND IN-PERSON ASSESSMENT (Days 1–3 in Country) On arrival, the patient undergoes in-hospital registration and is seen by the surgical oncologist. Imaging is reviewed on hospital PACS; repeat or additional investigations (updated MRI, dental OPG, pre-anaesthetic echo, PFTs if applicable) are completed within 24–48 hours. Formal MDT case presentation occurs on Day 2–3. Anaesthesiology pre-assessment, dental clearance, speech-language pathology baseline swallowing assessment (FEES or videofluoroscopy), and nutritional optimisation are completed. Informed consent covering surgical scope, facial nerve risks, reconstruction plan, and expected adjuvant therapy is obtained with interpreter support. PHASE 3 — SURGICAL INTERVENTION (Day 3–5) Surgery is performed under general anaesthesia. Duration ranges from 2–3 hours for a straightforward superficial parotidectomy to 8–12 hours for a radical parotidectomy with facial nerve reconstruction, segmental mandibulectomy, free-flap reconstruction, and bilateral neck dissection. Intraoperative continuous facial nerve EMG monitoring is used throughout parotid surgery. Frozen-section margin assessment is performed; if margins are positive, re-excision is attempted in the same sitting. A Jackson-Pratt drain is placed in the neck dissection field. For cases involving free-flap reconstruction, the patient is typically monitored in ICU overnight with hourly flap checks. PHASE 4 — EARLY POST-OPERATIVE RECOVERY (Days 5–10 in Hospital) Drain output is monitored daily; drains are removed when output falls below 30 mL/24 hours (typically Day 3–5 post-op). Nasogastric or oral feeding is initiated based on swallowing assessment — patients with intact oral competence begin clear liquids on Day 1–2 post-op and advance to a blended diet. Physiotherapy for shoulder rehabilitation (accessory nerve-sparing neck dissection) begins on Day 2. Wound inspection for Frey's syndrome precursors and Sialocele is performed at each dressing change. Facial nerve function is formally graded using the House-Brackmann scale at discharge. Pathology of the resected specimen (including final margin status, lymph node count, extranodal extension) is issued within 5–7 business days. PHASE 5 — ADJUVANT THERAPY PLANNING (Weeks 2–4 in Country) Oncology MDT reconvenes with final pathology to confirm adjuvant therapy recommendation. Radiation oncology marks treatment volumes: a radiation planning CT simulation with customised thermoplastic mask fabrication is performed. IMRT/VMAT planning is completed within 5–7 days. Adjuvant radiotherapy (typically 6 weeks, 30 fractions) begins 4–6 weeks post-surgery when wound healing is confirmed. If concurrent chemotherapy is indicated, weekly carboplatin (AUC 2) or weekly cisplatin is administered during radiation. Patients requiring radiotherapy are expected to remain in the country for the full 6-week course. PHASE 6 — SYSTEMIC THERAPY (If Applicable, Ongoing) For patients with metastatic or unresectable disease starting targeted therapy (trastuzumab, larotrectinib, enzalutamide), the first 1–2 treatment cycles are administered in-country with response and toxicity assessment. A follow-up care plan is issued to the patient's home oncologist for continuation, including drug sourcing guidance (both agents are available in most countries). PHASE 7 — DISCHARGE AND FIT-TO-FLY ASSESSMENT (Weeks 4–8) For patients who required surgery only (no adjuvant radiation), fit-to-fly assessment typically occurs at Week 4–6 post-operatively: wound fully healed, no active fistula or sialocele, post-operative CT/MRI baseline imaging completed, swallowing adequate to maintain oral hydration during flight, no active systemic anticoagulation concerns, and surgical oncologist clearance documented. For patients who completed adjuvant radiotherapy, fit-to-fly is assessed at 1–2 weeks post-radiation completion (Week 8–10 total). A detailed discharge summary, pathology reports, radiation treatment records (including DVH dosimetry files for home oncologist), and follow-up surveillance schedule are provided in both English and the patient's preferred language. SURVEILLANCE MILESTONES (Remote Follow-Up via GAF Healthcare Telemedicine): • Month 1 post-discharge: clinical review, wound check (virtual with photographs) • Month 3: contrast-enhanced MRI of the primary site and neck; clinical examination • Month 6: MRI primary + CT chest (high-grade histology); speech and swallowing re-assessment • Year 1–2: every 6 months — MRI, clinical exam, thyroid function (if neck irradiated) • Year 3–5: annually — MRI primary site, CT chest; dental review • Adenoid cystic carcinoma: annual imaging extended to 15–20 years due to late distant relapse pattern
Risks to be aware of
Salivary gland cancer surgery and multimodal treatment carry a defined spectrum of risks that patients must understand before committing to a treatment plan. The most consequential surgical risk is facial nerve injury during parotidectomy: temporary neuropraxia (weakness without axonal disruption) occurs in 15–30% of cases and usually resolves within 3–6 months; permanent palsy due to deliberate nerve sacrifice for oncological clearance occurs in 5–15% of radical resections and necessitates facial reanimation procedures. Frey's syndrome (gustatory sweating from aberrant auriculotemporal nerve regeneration) occurs in up to 40% of parotidectomies and may require botulinum toxin A injections for symptomatic management. Sialocele or salivary fistula formation occurs in 4–10% of cases and is managed conservatively with pressure dressings, repeated aspiration, or botulinum toxin injection. Free-flap reconstruction carries a 3–5% risk of partial or total flap failure; close post-operative monitoring with Doppler surveillance is essential in the first 72 hours. Neck dissection risks include chyle leak (thoracic duct injury, 1–3% of left-sided dissections), accessory nerve weakness with shoulder drop, and lymphoedema. Radiation-related risks include radiation-induced xerostomia (dry mouth) from contralateral parotid dose — mitigated but not eliminated by IMRT; mucositis during treatment; osteoradionecrosis of the mandible (2–5% lifetime risk, higher with poor dental hygiene or post-radiation dental extraction); radiation-induced sensorineural hearing loss; hypothyroidism (40–50% incidence if the thyroid is within the radiation field); and the rare but serious risk of radiation-induced secondary malignancy after a latency of 5–15 years. Trismus (restricted mouth opening) is a late toxicity of parotid bed irradiation and is managed with physiotherapy jaw-opening exercises initiated during radiation. Systemic therapy risks depend on the agent: cisplatin carries nephrotoxicity and ototoxicity requiring hydration protocols and audiometric monitoring; trastuzumab is associated with cardiotoxicity (LVEF reduction in 3–7%) necessitating baseline and interval ECHO; NTRK inhibitors (larotrectinib, entrectinib) are generally well tolerated but carry risks of dizziness, nausea, and transaminase elevation; androgen deprivation therapy causes hot flushes, loss of libido, bone density reduction (DEXA scan monitoring recommended), and metabolic syndrome. Patients must disclose all comorbidities and concurrent medications to their GAF Healthcare-assigned oncologist before therapy initiation to allow individualised risk mitigation.
Why GAF Healthcare
GAF Healthcare provides an end-to-end concierge infrastructure designed specifically for international oncology patients, ensuring that non-medical barriers never delay timely cancer treatment. INDIA — MEDICAL VISA AND ENTRY: GAF Healthcare prepares and submits the complete e-Medical Visa (e-MV) application on the patient's behalf, including the official hospital invitation letter, oncology treatment plan, and financial guarantee documentation required by the Indian High Commission. The e-MV is typically issued within 3–5 business days and allows a stay of up to 60 days per visit with triple-entry (extendable to 180 days for ongoing radiation or systemic therapy). One medical attendant accompanying the patient is eligible for an e-Medical Attendant Visa simultaneously. GAF Healthcare also assists with FRRO (Foreigners Regional Registration Office) registration in cities where this is mandatory for stays exceeding 14 days. UAE — VISA AND ENTRY: Citizens of GCC countries, most EU nations, UK, USA, Canada, Australia, and many Asian nations receive a visa-on-arrival or visa-free entry to the UAE for 30–90 days. Patients from countries requiring pre-arranged visas are assisted by GAF Healthcare through the UAE General Directorate of Residency and Foreigners Affairs (GDRFA) medical treatment visa pathway, coordinated with the receiving JCI/DHA-accredited hospital. AIRPORT TRANSFERS AND IN-COUNTRY TRANSPORT: Dedicated, air-conditioned private vehicles with trained patient transport coordinators meet patients at the airport arrivals gate in Mumbai, Delhi, Chennai, Bengaluru, Hyderabad, Dubai, or Abu Dhabi. All inter-facility transfers (hotel to hospital, hospital to radiation centre) are pre-scheduled and included in the GAF Healthcare package. Wheelchair-accessible vehicles and stretcher-equipped medical transport are available on request for patients with reduced mobility. DEDICATED MULTILINGUAL CASE COORDINATORS: Each patient is assigned a named GAF Healthcare case coordinator who speaks the patient's preferred language (Arabic, Russian, Swahili, French, Amharic, Uzbek, and others available). The coordinator attends all key consultations, surgical consent discussions, and radiation planning sessions to provide real-time medical interpretation and ensure nothing is lost in translation between the clinical team and the patient. ACCOMMODATION FOR PATIENT AND ATTENDANT: GAF Healthcare partners with hospitals that provide on-campus or adjacent guest houses for one attendant at a nominal daily rate. For extended stays (adjuvant radiotherapy — 6 weeks), we negotiate preferential rates at serviced apartments within 1–3 km of the treatment centre, equipped with kitchenettes for dietary flexibility, reliable internet, and 24-hour security. Meal-delivery arrangements aligned with the patient's dietary and swallowing requirements are coordinated with hospital dietitians. TELEMEDICINE AND POST-DISCHARGE FOLLOW-UP: GAF Healthcare's telemedicine platform enables direct video consultations with the treating surgical oncologist and radiation oncologist at 1-month, 3-month, and 6-month intervals post-departure. Imaging results from the patient's home country can be uploaded to the platform for remote radiological review. All treatment documentation — operative reports, histopathology, dosimetry plans, systemic therapy records — is maintained in a secure digital patient portal accessible by both the patient and their home physician.
Common questions about Salivary Gland Cancer Treatment
What is the cost of Salivary Gland Cancer Treatment in India compared to the UAE?
How long do I need to stay in the country before I am fit to fly home after Salivary Gland Cancer Treatment?
What is the success rate of Salivary Gland Cancer Treatment?
Related pages
How GAF Healthcare Assists in Choosing the Best Hospital for Salivary Gland Cancer Treatment in Mumbai, India
Discover the Top Hospitals for Salivary Gland Cancer Treatment in Mumbai, India
This page lists 17 accredited medical oncology hospitals in Mumbai, India, so you can compare accreditation, specialties and bed capacity in one place.
Support When You Need It Most
Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.
Transparent, All-Inclusive Costs
We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.
Visa, Travel and Stay Coordination
Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.
Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.
Frequently asked questions about salivary gland cancer treatment in Mumbai, India
How many medical oncology hospitals are listed in Mumbai, India?
How do you choose which hospitals to list?
How much does treatment cost in India?
Are there medical oncology hospitals for this in other India cities?
Next Step
Share your medical reports with us and our team will recommend a hospital and treatment plan for salivary gland cancer treatment in Mumbai, India.
Contact us to report an inaccuracy on this page.